Viking Therapeutics Shares Dip as Pfizer Chooses Rival Acquisition

Viking Therapeutics experienced significant selling pressure yesterday as investors reacted to Pfizer’s unexpected acquisition of competitor Metsera. The biotech firm’s shares declined 4.88% to close at $24.97, a notable setback for shareholders who had anticipated Viking itself might become a takeover target.

A Shifting Competitive Landscape

The pharmaceutical giant’s move to acquire Metsera represents a significant reshuffling of the competitive dynamics within the obesity drug market. This development is particularly impactful for Viking, as Pfizer had long been considered a prime candidate to acquire the company. This speculation intensified after Pfizer discontinued its internal GLP-1 drug development program, leaving Viking without a previously speculated potential buyer.

The news arrives at a challenging period for Viking Therapeutics. In August, the company’s VENTURE-Oral study yielded mixed results. While the oral formulation of its drug candidate VK2735 demonstrated substantial weight reduction efficacy, investor confidence was rattled by high dropout rates observed among trial participants.

Critical Clinical Milestones on the Horizon

The company is now entering a decisive stage. Its lead injectable version of VK2735 is progressing through Phase 3 clinical trials for obesity treatment. The outcome of these VANQUISH trials is poised to be a major determinant of the company’s future trajectory.

Should investors sell immediately? Or is it worth buying Viking Therapeutics?

Key Upcoming Events:
– September 30: Participation in the Stifel Virtual Cardiometabolic Forum
– Late October: Q3 2025 quarterly financial results
– Ongoing: Updates from the Phase 3 clinical trial program

Navigating a Crowded Market

The race to capture a share of the multi-billion dollar obesity treatment market is intensifying. Pfizer’s strategic acquisition strengthens its position, meaning Viking must now compete independently against established pharmaceutical leaders. Although Viking’s pipeline includes additional assets like VK2809 for metabolic disorders such as NASH, the primary focus remains squarely on achieving success with its potential blockbuster weight-loss therapy.

The central question for investors is whether Viking can sustain its momentum without the allure of a potential buyout. Forthcoming data from its advanced clinical studies will be crucial in demonstrating if the company possesses the standalone strength to compete effectively in this high-stakes therapeutic area.